Abstract:123 While transplantation remains the only potentially useful treatment for end-stage organ failure, immunological rejection of allografts continues to be a major problem. We have investigated if the fate of T cell precursors developing in the thymus may be determined by the presence of allo MHC class I peptides, since T cell receptor-MHC class I / self peptide interaction regulates thymocyte development. This study examined the effects and underlying mechanisms of intrathymic (IT) injection of a short segment of a synthetic immunogenic MHC class I peptide [P-2; Residues 67 - 85] of the hypervariable domain of RT1.A derived from WAG rat [RT1u] on islet graft survival in the WF [RT1u]-to-ACI [RT1a]. The results showed that while IT injection of 150 µg P-2 on day -7 did not prolong graft survival in naive recipients [MST of 14.0 days vs 9.6 days in controls], IT injection of 300 µg or 600 µg P-2 led to normoglycemia and permanent islet survival [>200 days] in 4/6 and 3/5 STZ induced diabetic ACI recipients, respectively. IT injection of 150 µg, 300 µg, or 600 µg P-2 combined with 0.5 ml ALS immunosuppression on day -7 led to 100% permanent islet graft survival [>200 days] compared to MST of 15.0 ± 2.3 days in ALS alone treated controls. Similarly prepared animals rejected 3rd party [BN] islets in an acute fashion, thus demonstrating donor specificity. Intravenous injection of 300 µg P-2 combined with 0.5 ml ALS did not prolong islet allografts. The long-term unresponsive islet allograft recipients challenged with 2nd set grafts accepted permanently 4/4 donor-type cardiac allografts while rejecting 3rd party [Lewis] hearts without rejecting the primary [WF] islets. In analyzing the underlying mechanisms of acquired systemic tolerance, we found no suppresser / regulatory cells in the adoptive transfer studies in tolerant animals at 30 days after IT injection of allopeptides. In contrast, adoptive transfer of 5 × 107 unseparated spleen cells or 2 × 107 purified T-cells obtained from tolerant animals 60 and 120 days after islet transplantation into lightly irradiated [200 rad TBI] ACI led to donor-specific permanent islet graft survival in 75 and 100% animals respectively compared to an MST of 14.5 days in lightly irradiated ACI recipients of unmodified syngenic spleen cells. Our findings suggest that maintenance of acquired thymic tolerance induced by class I MHC allopeptides is dependent on generation of regulatory cells and that this strategy may have potential clinical application in the induction of acquired tolerance.

Anti-TCR Mab Induces Peripheral Tolerance to Alloantigens and Delays Islet Allograft Rejection in Autoimmune Diabetic NOD Mice.

PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

REGULATORY T CELLS MAINTAIN PERIPHERAL TOLERANCE TO ISLET ALLOGRAFTS INDUCED BY INTRATHYMIC INJECTION OF MHC CLASS I ALLOPEPTIDES

CAR Tregs protect alloimmune islets against autoimmune destruction

Regulatory T Cell Therapy for the Induction of Clinical Organ Transplantation Tolerance

Anti-CD25 mAb, Anti-IL2 mAb, and IL2 Block Tolerance Induction Through Anti-CD154 mAb and Rapamycin in Xenogeneic Islet Transplantation

CAR Tregs mediate linked suppression and infectious tolerance in islet transplantation

Essential Roles Of Tgf-Beta In Anti-Cd3 Antibody Therapy: Reversal Of Diabetes In Nonobese Diabetic Mice Independent Of Foxp3(+) Cd4(+) Regulatory T Cells

A Novel Clinically Relevant Strategy To Abrogate Autoimmunity And Regulate Alloimmunity In Nod Mice

Natural Killer Cells Modulate Overt Autoimmunity to Homeostasis in Nonobese Diabetic Mice after Anti-CD3 F(ab′)2 Antibody Treatment through Secreting Transforming Growth Factor-β

Long-term Tolerance to Islet Transplantation via Targeted Reduction of beta cell-specific T cells.

Ex Vivo Expanded Human Regulatory T Cells Delay Islet Allograft Rejection Via Inhibiting Islet-Derived Monocyte Chemoattractant Protein-1 Production in CD34+ Stem Cells-Reconstituted NOD-scid IL2rγnull Mice.

Immune protective effect of human alpha-1-antitrypsin gene during β cell transplantation in diabetic mice

CD3-specific antibody-induced active tolerance: from bench to bedside

Induction of Active Tolerance and Involvement of Cd1d-Restricted Natural Killer T Cells in Anti-Cd3 F(Ab ')(2) Treatment-Reversed New-Onset Diabetes in Nonobese Diabetic Mice

Adoptive Transfer with in Vitro Expanded Human Regulatory T Cells Protects Against Porcine Islet Xenograft Rejection Via Interleukin-10 in Humanized Mice

Murine Islet Allograft Tolerance Upon Blockade of the B-Lymphocyte Stimulator, BLyS/BAFF

Alpha-1-antitrypsin for the improvement of autoimmunity and allograft rejection in beta cell transplantation

Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells